Designs on NS5b

The HCV polymerase non-structural protein 5b has been known for many years, but to date no company has successfully targeted it because of toxicology issues or lack of potency. Anadys Pharmaceuticals Inc. believes its structure-based drug design and medicinal chemistry approaches have overcome those problems. Late last month, the company reported preliminary results from a Phase I trial of its NS5b inhibitor, ANA598.

NS5b is

Read the full 640 word article

How to gain access

Continue reading with a
two-week free trial.